Models of tauopathy

US12110502B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Marine Prissette · Brooklyn, US
• Matthew Koss · Pleasantville, US
• Mathieu Desclaux · Brooklyn, US
• John McWhirter · Tarrytown, US
• Arijit Bhowmick · New York, US
• David Frendewey · New York, US
• Brian Zambrowicz · Diemelstraße, US
• Claudia Racioppi · New York, US

Key dates

• Filing date: Nov 6, 2023
• Grant date: Oct 8, 2024
• Expiry date: Nov 6, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.